{"product_id":"immunocore-business-model-canvas","title":"Immunocore Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the core components of Immunocore's innovative approach with our detailed Business Model Canvas. Understand their unique value proposition, customer relationships, and key resources that drive their success in the biopharmaceutical sector. This comprehensive analysis is your key to unlocking their strategic framework.\u003c\/p\u003e\n\u003cp\u003eReady to dissect Immunocore's winning strategy? Our full Business Model Canvas provides an in-depth look at their revenue streams, cost structure, and channels. Download it now to gain actionable insights for your own business ventures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore actively collaborates with top-tier academic and research institutions. These partnerships are vital for groundbreaking early-stage research, pinpointing new therapeutic targets, and gaining a deeper understanding of complex disease pathways.\u003c\/p\u003e\n\u003cp\u003eBy teaming up with these institutions, Immunocore taps into advanced scientific knowledge and utilizes specialized research facilities. This synergy significantly speeds up the discovery and preclinical development of novel ImmTAC molecules, aimed at treating a wide range of diseases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations (CROs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore’s reliance on Clinical Research Organizations (CROs) is critical for the successful execution of its global clinical development programs.  These partnerships are vital for navigating the complexities of designing, conducting, and managing trials efficiently across diverse regions.\u003c\/p\u003e\n\u003cp\u003eCROs offer specialized expertise in crucial areas such as regulatory affairs, ensuring compliance with varying international standards, and patient recruitment, a key challenge in rare disease and oncology trials. Their capabilities in data management and statistical analysis are essential for generating robust evidence to support regulatory submissions, as seen with the development of ImmTACs like KIMMTRAK.\u003c\/p\u003e\n\u003cp\u003eBy outsourcing these functions, Immunocore can focus on its core competencies in drug discovery and development.  The global CRO market size was estimated to be over $50 billion in 2023, highlighting the significant investment companies like Immunocore make in these specialized services to accelerate their pipeline progression.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companies for Co-development\/Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore actively pursues strategic alliances with major biopharmaceutical firms to co-develop and license its ImmTAC platform. These collaborations are crucial for securing substantial funding, mitigating development risks, and leveraging partners' extensive commercialization expertise.\u003c\/p\u003e\n\u003cp\u003eFor instance, in April 2024, Immunocore announced an expansion of its existing collaboration with Genmab, focusing on the development of novel bispecific antibodies targeting specific cancer indications. This partnership aims to accelerate the clinical progression of ImmTAC candidates and broaden their therapeutic applications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore’s manufacturing and supply chain partners are essential for delivering its innovative ImmTAC molecules. These collaborations ensure the consistent production of high-quality therapies and their availability to patients worldwide.  For instance, in 2024, the company continued to rely on specialized contract manufacturing organizations (CMOs) for both drug substance and drug product, a common strategy in the biopharmaceutical industry to manage complex production processes and scale.\u003c\/p\u003e\n\u003cp\u003eThese vital partnerships encompass critical functions beyond just production. They include rigorous quality control measures to meet stringent regulatory standards, efficient logistics for timely delivery, and robust distribution networks to reach global markets.  The successful commercialization of KIMMTRAK, Immunocore’s first approved therapy, and the anticipated launches of its pipeline candidates are heavily dependent on the reliability and expertise of these manufacturing and supply chain allies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDrug Substance Manufacturing:\u003c\/strong\u003e Partnerships with specialized facilities capable of complex biopharmaceutical synthesis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDrug Product Manufacturing:\u003c\/strong\u003e Collaborations for formulation, filling, and finishing of the final therapeutic product.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuality Control and Assurance:\u003c\/strong\u003e Agreements with accredited laboratories to ensure product safety, efficacy, and compliance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLogistics and Distribution:\u003c\/strong\u003e Networks for cold chain management and global supply chain operations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Foundations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore actively collaborates with patient advocacy groups and disease-specific foundations. These partnerships are crucial for gaining a deep understanding of patient needs, amplifying disease awareness, and ensuring patient access to therapies such as KIMMTRAK. For instance, by working with groups focused on uveal melanoma, Immunocore can better tailor its support programs.\u003c\/p\u003e\n\u003cp\u003eThese collaborations also play a vital role in bolstering clinical trial recruitment efforts. By engaging with patient communities, Immunocore can streamline the process of identifying and enrolling eligible participants. This was evident in the recruitment for the Phase 3 IMCgp100-202 trial, which led to the approval of KIMMTRAK.\u003c\/p\u003e\n\u003cp\u003eFurthermore, these partnerships provide invaluable insights into the lived experiences of patients. This feedback directly informs the development of patient-centric support programs, enhancing the overall patient journey. In 2024, the company continued to strengthen these relationships, recognizing their impact on both clinical development and post-market support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePatient Needs Understanding\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDisease Awareness and Access Facilitation\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eClinical Trial Recruitment Support\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePatient Experience Insights for Support Programs\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Powering Biopharmaceutical Innovation and Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore’s key partnerships extend to contract manufacturing organizations (CMOs) and specialized logistics providers. These collaborations are essential for the reliable production and global distribution of its ImmTAC therapies, including KIMMTRAK. The company relies on these partners for complex biopharmaceutical synthesis, formulation, and adherence to stringent quality control standards, ensuring patient access to critical treatments.\u003c\/p\u003e\n\u003cp\u003eThe company also engages with major biopharmaceutical firms through strategic alliances for co-development and licensing. These partnerships, such as the expanded collaboration with Genmab announced in April 2024, provide significant funding, share development risks, and leverage extensive commercialization expertise, accelerating the progression of ImmTAC candidates.\u003c\/p\u003e\n\u003cp\u003eCrucially, Immunocore collaborates with top-tier academic and research institutions to drive early-stage discovery and target identification. These academic ties, alongside partnerships with Clinical Research Organizations (CROs), are vital for navigating complex clinical trials and generating robust data, with the global CRO market exceeding $50 billion in 2023.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003ePurpose\u003c\/th\u003e\n\u003cth\u003eExample\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic \u0026amp; Research Institutions\u003c\/td\u003e\n\u003ctd\u003eEarly-stage research, target identification\u003c\/td\u003e\n\u003ctd\u003eAccess to advanced scientific knowledge and facilities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Research Organizations (CROs)\u003c\/td\u003e\n\u003ctd\u003eClinical trial execution, regulatory compliance\u003c\/td\u003e\n\u003ctd\u003eGlobal CRO market over $50 billion (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharmaceutical Firms\u003c\/td\u003e\n\u003ctd\u003eCo-development, licensing, commercialization\u003c\/td\u003e\n\u003ctd\u003eExpanded collaboration with Genmab (April 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Manufacturing Organizations (CMOs) \u0026amp; Logistics\u003c\/td\u003e\n\u003ctd\u003eTherapy production, global distribution\u003c\/td\u003e\n\u003ctd\u003eEnsuring consistent quality and patient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis Immunocore Business Model Canvas provides a strategic overview of their TCR immunotherapy platform, detailing customer segments (patients, healthcare providers), value propositions (novel cancer treatments), and key partnerships.\u003c\/p\u003e\n\u003cp\u003eIt outlines revenue streams from drug sales and collaborations, cost structure focused on R\u0026amp;D, and key resources like intellectual property and scientific expertise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eImmunocore's Business Model Canvas acts as a pain point reliever by providing a clear, one-page snapshot of their innovative approach to developing T-cell receptor (TCR) therapies.\u003c\/p\u003e\n\u003cp\u003eThis concise framework helps stakeholders quickly grasp the core components of their value proposition and customer segments, alleviating the pain of understanding complex, cutting-edge biotechnology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D) of ImmTAC Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore's central focus is the discovery and development of innovative T cell receptor (TCR) bispecific immunotherapies, known as ImmTACs. This rigorous process includes extensive preclinical research, validating potential targets, and optimizing lead candidates to address a range of cancers, infectious diseases, and autoimmune disorders, thereby consistently growing their unique platform.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to innovation is reflected in its financial investments. In 2024, Immunocore allocated $222.2 million to research and development. This investment continued into the first quarter of 2025, with $56.5 million dedicated to R\u0026amp;D, a slight decrease from the $57.5 million spent in the first quarter of 2024, underscoring their ongoing pursuit of novel therapeutic solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore's core activity revolves around the meticulous management and execution of clinical trials for its innovative ImmTAC therapies. This encompasses the entire lifecycle from initial design and patient recruitment to ongoing monitoring and data analysis across all trial phases.\u003c\/p\u003e\n\u003cp\u003eA significant focus is placed on ensuring the highest standards of data integrity and patient safety throughout the trials. This rigorous oversight is crucial for meeting the stringent requirements of regulatory bodies and achieving key clinical milestones necessary for drug approvals.\u003c\/p\u003e\n\u003cp\u003eAs of mid-2024, Immunocore is actively enrolling patients in three pivotal Phase 3 trials for its melanoma treatments. Concurrently, the company is progressing with Phase 1\/2 trials for other promising oncology indications and exploring its pipeline for infectious diseases, demonstrating a broad commitment to advancing its therapeutic candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control of Therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing ImmTAC therapeutics, like KIMMTRAK, involves intricate steps from cell line development to final formulation. This ensures each batch meets stringent quality and consistency benchmarks required by global health authorities.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Immunocore continued to optimize its manufacturing processes, investing in advanced technologies to scale production. This focus is critical for meeting the growing demand for their innovative treatments and maintaining compliance with evolving regulatory landscapes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating the complex global regulatory environment is a core activity for Immunocore. This involves meticulously preparing and submitting extensive regulatory dossiers to health authorities worldwide. The company actively engages with these agencies to secure and maintain approvals for its innovative therapies. \u003c\/p\u003e\n\u003cp\u003eA crucial aspect of this is developing tailored market access and reimbursement strategies for each country. This ensures that patients who can benefit from Immunocore's treatments can actually receive them. As of March 31, 2025, KIMMTRAK has achieved approval in 39 countries and has been successfully launched in 26 markets globally, demonstrating significant progress in this area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Regulatory Navigation\u003c\/strong\u003e: Securing and maintaining approvals for therapies like KIMMTRAK across diverse international health authorities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDossier Preparation and Submission\u003c\/strong\u003e: Compiling and submitting comprehensive documentation to regulatory bodies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHealth Authority Engagement\u003c\/strong\u003e: Proactive communication and collaboration with agencies like the FDA and EMA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access and Reimbursement Strategy\u003c\/strong\u003e: Developing country-specific plans to ensure patient access and favorable reimbursement terms post-approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales of Approved Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKey activities for commercialization and sales of approved products, such as KIMMTRAK, focus on building and managing effective sales teams, executing targeted marketing and promotional campaigns, and establishing robust distribution channels to ensure access for healthcare providers and patients. This involves implementing strategic approaches for market penetration, driving product adoption, and expanding global reach to optimize revenue generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Force Establishment:\u003c\/strong\u003e Developing and deploying specialized sales forces to engage with oncologists and other relevant medical professionals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing and Promotion:\u003c\/strong\u003e Implementing comprehensive marketing strategies, including medical education, digital outreach, and conference participation, to build awareness and drive demand for KIMMTRAK.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Networks:\u003c\/strong\u003e Establishing efficient and reliable distribution channels to ensure timely and consistent availability of the product to patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Penetration and Expansion:\u003c\/strong\u003e Focusing on strategies to increase market share and expand geographical presence to maximize revenue potential, as evidenced by KIMMTRAK's full-year 2024 net sales of $310.0 million and Q1 2025 net sales of $93.9 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmTAC Platform: Driving Innovation from R\u0026amp;D to Global Market Success\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore’s key activities center on the development and commercialization of its ImmTAC platform. This involves rigorous R\u0026amp;D, including extensive preclinical work and clinical trial management, exemplified by their investment of $222.2 million in R\u0026amp;D during 2024. The company also focuses on manufacturing its therapies to high standards and navigating complex global regulatory pathways to secure approvals and market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eKey Metrics\/Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDiscovery and optimization of ImmTAC therapies.\u003c\/td\u003e\n\u003ctd\u003e$222.2M R\u0026amp;D spend in 2024; $56.5M in Q1 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eManagement of trials from design to data analysis.\u003c\/td\u003e\n\u003ctd\u003ePhase 3 trials for melanoma ongoing; Phase 1\/2 for other indications.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eProduction of ImmTACs ensuring quality and consistency.\u003c\/td\u003e\n\u003ctd\u003eOptimization of processes for scaled production in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eSecuring and maintaining global drug approvals.\u003c\/td\u003e\n\u003ctd\u003eKIMMTRAK approved in 39 countries as of March 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eSales, marketing, and distribution of approved therapies.\u003c\/td\u003e\n\u003ctd\u003eKIMMTRAK net sales: $310.0M (FY 2024), $93.9M (Q1 2025).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Immunocore Business Model Canvas preview you are viewing is precisely the document you will receive upon purchase. This means you're seeing the actual, complete file, not a sample or mockup. Once your order is processed, you will gain full access to this same comprehensive Business Model Canvas, ready for your immediate use and analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611236286841,"sku":"immunocore-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/immunocore-business-model-canvas.png?v=1754753511","url":"https:\/\/growthsharematrix.com\/products\/immunocore-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}